Clovis: Phase 1 Data of Targeted Radiotherapy Candidate

 

• Updated LuMIERE Phase 1 data demonstrated a manageable safety profile with some preliminary evidence of anti-tumor activity

  • Eleven patients treated to date with 177Lu-FAP-2286 up to 7.4 GBq/dose

  • No serious adverse events, treatment discontinuations, or deaths related to 177Lu-FAP-2286 observed

  • Confirmed partial response (PR) in one patient who completed the maximum six administrations of 177Lu-FAP-2286 in the 3.7 GBq dose cohort

    • Patient continues without disease progression or subsequent anti-cancer therapy more than twelve months after first dose

  • Stable disease (SD) in one heavily pretreated patient who completed four administrations of 177Lu-FAP-2286 in the 5.55 GBq dose cohort

  • Recruitment of the 7.4 GBq dose cohort is ongoing

• FAP-2286 has shown high tumor uptake and good prolonged retention across a range of solid tumors

https://finance.yahoo.com/news/clovis-oncology-highlights-updated-lumiere-074500928.html